Literature DB >> 8512045

Considerations for contraception in women with cardiovascular disorders.

J M Sullivan1, R A Lobo.   

Abstract

Women with hypertension, angina pectoris, or mitral valve prolapse require special considerations when selecting an appropriate method of contraception. All three effective, reversible options (oral contraceptives, intrauterine devices, or progestin implants) carry some degree of added risk for these patient populations. However, pregnancy itself presents certain risks and, in the event of contraceptive failure, certain women with these disorders are at increased risk of developing serious cardiovascular sequelae that affect both mother and fetus. These negative effects can carry far into the neonatal period. This article describes the risk/benefit profiles of the currently available contraceptive options relative to their potential impact in these compromised women.

Entities:  

Keywords:  Arterial Occlusive Diseases; Arteriosclerosis; Atherosclerosis; Biology; Cardiovascular Effects; Contraception; Contraceptive Implants; Contraceptive Methods; Contraceptive Usage; Diseases; Family Planning; Heart Diseases; Hypertension--women; Iud; Literature Review; Oral Contraceptives; Physiology; Pregnancy; Recommendations; Reproduction; Risk Factors; Vascular Diseases

Mesh:

Substances:

Year:  1993        PMID: 8512045     DOI: 10.1016/s0002-9378(12)90942-4

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  4 in total

Review 1.  Recent developments in hormonal contraception.

Authors:  Eleanor A Drey; Philip D Darney
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

Review 2.  The management of pregnancy in hypertensive patients.

Authors:  R D Tunbridge
Journal:  Postgrad Med J       Date:  1994-11       Impact factor: 2.401

3.  High Prevalence of Asymptomatic Intracranial Atherosclerosis in Elder Women With Tubal Ligation: Result From a Community-Based Study in Shandong, China.

Authors:  Xiaotong Ma; Shaowei Sang; Yuanyuan Zhao; Xiang Wang; Xiaokang Ji; Sai Shao; Guangbin Wang; Fuzhong Xue; Yifeng Du; Ming Lv; Qinjian Sun
Journal:  Front Cardiovasc Med       Date:  2022-03-02

4.  Pharmacokinetic comparison of the vasorelaxant compound ferulic acid following the administration of Guanxin II to healthy volunteers and patients with angina pectoris.

Authors:  Yun-Hui Li; Xi Huang; Yang Wang; Rong Fan; Hong-Min Zhang; Ping Ren; Yao Chen; Hong-Hao Zhou; Zhao-Qian Liu; Yi-Zeng Liang; Hong-Mei Lu
Journal:  Exp Ther Med       Date:  2013-09-17       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.